Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA's Drug Shortage Effort Questioned By GAO

Executive Summary

GAO's 'high risk' report lowers FDA grade for its drug shortage action plans, saying efforts have not been sustained.

You may also be interested in...



US FDA’s Foreign Inspection Agenda: Visit The 1,000 Facilities It’s Never Seen

Congressional oversight agency urges FDA to make better use of foreign offices with more effective performance measures and staffing goals; GAO notes agency’s progress towards risk-based inspections – and its plan to revisit every site at least once every five years.

FDA's Information Security Fixes Expected To Be Completed Within A Year

GAO report prompts vigorous action – and some defensiveness – by the agency.

FDA’s Priority Reviews May Have Helped Reduce New Drug Shortages

But agency's policy changes have failed to ameliorate ongoing shortages, GAO finds.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS120062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel